Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitor-Based Treatment on Cardiovascular Outcomes in Hypertensive Blacks Versus Whites
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND Clinical trial evidence suggests poorer outcomes in blacks compared to whites when treated with angiotensin-converting enzyme (ACE) inhibitor-based regimen, but this has not been evaluated in clinical practice. OBJECTIVES We evaluated the comparative effectiveness of an ACE inhibitor-based regimen on a composite outcome of all-cause mortality, stroke, and acute myocardial infarction (AMI) in hypertensive blacks compared to whites. METHODS We conducted a retrospective cohort study of 434,646 patients in a municipal health care system. Four exposure groups (Black-ACE, Black-NoACE, White-ACE, White-NoACE) were created based on race and treatment exposure (ACE or NoACE). Risk of the composite outcome and its components was compared across treatment groups and race using weighted Cox proportional hazard models. RESULTS Our analysis included 59,316 new users of ACE inhibitors, 47% of whom were black. Baseline characteristics were comparable for all groups after inverse probability weighting adjustment. For the composite outcome, the race treatment interaction was significant (p = 0.04); ACE use in blacks was associated with poorer cardiovascular outcomes (ACE vs. NoACE: 8.69% vs. 7.74%; p = 0.05) but not in whites (6.40% vs. 6.74%; p = 0.37). Similarly, the Black-ACE group had higher rates of AMI (0.46% vs. 0.26%; p = 0.04), stroke (2.43% vs. 1.93%; p = 0.05) and chronic heart failure (3.75% vs. 2.25%; p < 0.0001) than the Black-NoACE group. However, the Black-ACE group was no more likely to develop adverse effects than the White-ACE group. CONCLUSIONS ACE inhibitor-based therapy was associated with poorer cardiovascular outcomes in hypertensive blacks but not in whites. These findings confirm clinical trial evidence that hypertensive blacks have poorer outcomes than whites when treated with an ACE inhibitor-based regimen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646 · cited 1×
“We identified new users (an inception cohort) for each antihypertensive medication, to prevent “healthy user” effects that result from studying patients who are not treatment naïve (15).”
BackgroundState of disparities in cardiovascular health in the United States.
Mensah, G. A., Mokdad, A. H., Ford, E. S., Greenlund, K. J., & Croft, J. B. (2005) · Circulation · doi:10.1161/01.cir.0000158136.76824.04 · Cited by 1,213
Hirano, K., & Imbens, G. W. (2001) · Health Services and Outcomes Research Methodology · doi:10.1023/a:1020371312283 · Cited by 1,039 · cited 7×
“SEE PAGE 1234 CV = cardiovascular CVD = cardiovascular disease CHF = congestive heart failure EHRs = electronic health records HHC = Health and Hospital Corporation HR = hazard ratio ICD-9 = International Classification of Diseases9th edition IPTW = inverse probability of treatment weights = systolic blood pressure An…”
MethodInfluentialContribution of major diseases to disparities in mortality.
Wong, M. D., Shapiro, M. F., Boscardin, W. J., & Ettner, S. L. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa012979 · Cited by 774 · cited 7×
“The baseline characteristics of all 4 study groups (Black-ACE, Black-NoACE, White-ACE, and White-NoACE) before IPTW matching are summarized in Tables 1 and 2.”
BackgroundInfluentialRepresentation of the Elderly, Women, and Minorities in Heart Failure Clinical Trials
Heiat, A., Gross, C. P., & Krumholz, H. M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.15.1682 · Cited by 723 · cited 7×
“%) than the Black-NoACE group.”
BackgroundInfluentialMorimoto, T., Gandhi, T. K., Fiskio, J. M., Seger, A. C., So, J. W., Cook, E. F., Fukui, T., & Bates, D. W. (2004) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2003.00484.x · Cited by 211
Cited by
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000596 · Cited by 1,127
Racial and ethnic differences in trends in dementia prevalence and risk factors in the United States
Chen, C., & Zissimopoulos, J. M. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.08.009 · Cited by 269
Metadata
- Authors
- Ogedegbe, G., Shah, N. R., Phillips, C., Goldfeld, K., Roy, J., Guo, Y., Gyamfi, J., Torgersen, C., Capponi, L., & Bangalore, S.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 66
- Issue
- 11
- Pages
- 1224-1233
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W1476288921
- Cited by
- 58
- References
- 7
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitor-Based Treatment on Cardiovascular Outcomes in Hypertensive Blacks Versus Whites. https://app.cochat.ai/papers/10.1016/j.jacc.2015.07.021
- The paper
- Ogedegbe, G., Shah, N. R., Phillips, C., Goldfeld, K., Roy, J., Guo, Y., Gyamfi, J., Torgersen, C., Capponi, L., & Bangalore, S. (2015). Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitor-Based Treatment on Cardiovascular Outcomes in Hypertensive Blacks Versus Whites. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2015.07.021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.